UICC期乳腺癌的影像学肿瘤征象:TOSYMA随机对照试验的亚分析。

IF 1.3 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Stefanie Weigel, Hans Werner Hense, Veronika Weyer-Elberich, Joachim Gerss, Walter Heindel
{"title":"UICC期乳腺癌的影像学肿瘤征象:TOSYMA随机对照试验的亚分析。","authors":"Stefanie Weigel, Hans Werner Hense, Veronika Weyer-Elberich, Joachim Gerss, Walter Heindel","doi":"10.1055/a-2544-9085","DOIUrl":null,"url":null,"abstract":"<p><p>The randomized controlled, multicenter TOSYMA study showed a superiority of the combination of digital breast tomosynthesis and synthetic mammography (DBT+SM) over digital mammography (DM) in the detection rate of invasive breast cancer at stage UICC I. In this subanalysis, we compared the mammographic tumor signs of UICC I stage breast cancers detected in each study arm and stratified according to histological grade.This subanalysis included 49,462 women in the DBT+SM arm and 49,669 women in the DM arm after 1:1 randomization from July 2018 to December 2020. The mammographic abnormalities documented at the consensus conference were collected for breast cancers in stage UICC I based on various tumor signs (such as masses, microcalcifications, architectural distortions, or their combinations). The detection rates (per 10,000 screened women) were calculated with differentiation of grade 1 and grade 2 or 3 cancers.Grade 1 cancers were detected using DBT+SM in 6.5/10,000 screened women only by masses (+1.5/10,000 versus DM), in 2.4/10,000 (+1.6/10,000) by architectural distortions, and in 1.2/10,000 (+0.8/10,000) by microcalcifications. Combinations of tumor signs were present in 7.9/10,000 (+6.1/10,000) screened women. Grade 2 or 3 cancers were detected by DBT+SM in 13.7/10,000 by masses (+2.6/10,000 versus DM), in 4.9/10,000 by microcalcifications (+2.3/10,000), and in 3.6/10,000 by architectural distortions (+2.0/10,000). Combinations were present in 10.1/10,000 (+6.3/10,000) screened women.In DBT+SM screening, the detection rate of UICC I breast cancers is higher compared to DM: both, individual tumor signs and their combinations contribute to this finding. The detection rate of UICC I grade 2 or 3 cancers is higher in DBT+SM screening than in DM screening mainly due to the combination of tumor signs. · DBT+SM detects more grade 2 or 3-UICC I breast cancers than DM.. · This increase in detection rate results mainly from a combination of tumor signs.. · Nearly half of the increase relates to individual signs: masses, microcalcifications, and architectural distortions.. · Weigel S, Hense HW, Weyer-Elberich V et al. Radiological Tumor Signs of Breast Cancer in UICC Stage I: Subanalysis of the Randomized Controlled Trial TOSYMA. Rofo 2025; DOI 10.1055/a-2544-9085.</p>","PeriodicalId":21490,"journal":{"name":"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Radiological Tumor Signs of Breast Cancer in UICC Stage I: Subanalysis of the Randomized Controlled Trial TOSYMA.\",\"authors\":\"Stefanie Weigel, Hans Werner Hense, Veronika Weyer-Elberich, Joachim Gerss, Walter Heindel\",\"doi\":\"10.1055/a-2544-9085\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The randomized controlled, multicenter TOSYMA study showed a superiority of the combination of digital breast tomosynthesis and synthetic mammography (DBT+SM) over digital mammography (DM) in the detection rate of invasive breast cancer at stage UICC I. In this subanalysis, we compared the mammographic tumor signs of UICC I stage breast cancers detected in each study arm and stratified according to histological grade.This subanalysis included 49,462 women in the DBT+SM arm and 49,669 women in the DM arm after 1:1 randomization from July 2018 to December 2020. The mammographic abnormalities documented at the consensus conference were collected for breast cancers in stage UICC I based on various tumor signs (such as masses, microcalcifications, architectural distortions, or their combinations). The detection rates (per 10,000 screened women) were calculated with differentiation of grade 1 and grade 2 or 3 cancers.Grade 1 cancers were detected using DBT+SM in 6.5/10,000 screened women only by masses (+1.5/10,000 versus DM), in 2.4/10,000 (+1.6/10,000) by architectural distortions, and in 1.2/10,000 (+0.8/10,000) by microcalcifications. Combinations of tumor signs were present in 7.9/10,000 (+6.1/10,000) screened women. Grade 2 or 3 cancers were detected by DBT+SM in 13.7/10,000 by masses (+2.6/10,000 versus DM), in 4.9/10,000 by microcalcifications (+2.3/10,000), and in 3.6/10,000 by architectural distortions (+2.0/10,000). Combinations were present in 10.1/10,000 (+6.3/10,000) screened women.In DBT+SM screening, the detection rate of UICC I breast cancers is higher compared to DM: both, individual tumor signs and their combinations contribute to this finding. The detection rate of UICC I grade 2 or 3 cancers is higher in DBT+SM screening than in DM screening mainly due to the combination of tumor signs. · DBT+SM detects more grade 2 or 3-UICC I breast cancers than DM.. · This increase in detection rate results mainly from a combination of tumor signs.. · Nearly half of the increase relates to individual signs: masses, microcalcifications, and architectural distortions.. · Weigel S, Hense HW, Weyer-Elberich V et al. Radiological Tumor Signs of Breast Cancer in UICC Stage I: Subanalysis of the Randomized Controlled Trial TOSYMA. Rofo 2025; DOI 10.1055/a-2544-9085.</p>\",\"PeriodicalId\":21490,\"journal\":{\"name\":\"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2544-9085\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2544-9085","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

随机对照、多中心的TOSYMA研究显示,在UICC I期浸润性乳腺癌的检出率方面,数字乳腺断层合成和合成乳房x线摄影(DBT+SM)的组合优于数字乳房x线摄影(DM)。在这个亚分析中,我们比较了每个研究组中检测到的UICC I期乳腺癌的乳房x线摄影肿瘤征象,并根据组织学分级进行了分层。该亚组分析包括2018年7月至2020年12月1:1随机分组后DBT+SM组的49,462名女性和DM组的49,669名女性。共识会议上记录的UICC I期乳腺癌的乳房x线摄影异常是基于各种肿瘤征象(如肿块、微钙化、结构扭曲或其组合)收集的。检出率(每10,000名筛查妇女)是根据1级和2级或3级癌症的分化来计算的。使用DBT+SM筛查的1级癌症患者中,只有6.5/ 10000的患者通过肿块(与DM相比增加1.5/ 10000),2.4/ 10000的患者通过结构扭曲(增加1.6/ 10000),1.2/ 10000的患者通过微钙化(增加0.8/ 10000)。在7.9/10,000(+6.1/10,000)的筛查妇女中存在肿瘤体征的组合。DBT+SM检测到2级或3级癌症的比例为13.7/10,000(与DM相比为+2.6/10,000),微钙化为4.9/10,000(+2.3/10,000),结构扭曲为3.6/10,000(+2.0/10,000)。有10.1/10,000(+6.3/10,000)筛查妇女出现联合。在DBT+SM筛查中,UICC I型乳腺癌的检出率高于DM:个体肿瘤体征及其组合都有助于这一发现。DBT+SM筛查UICC I 2级或3级肿瘤的检出率高于DM筛查,主要是由于肿瘤体征的结合。·DBT+SM比DM更能检测到2级或3-UICC I型乳腺癌。·这种检出率的提高主要是由于肿瘤体征的结合。·近一半的增加与个体体征有关:肿块、微钙化和建筑扭曲。·Weigel S, Hense HW, Weyer-Elberich V等。UICC期乳腺癌的影像学肿瘤征象:TOSYMA随机对照试验的亚分析。Rofo 2025;DOI 10.1055 / - 2544 - 9085。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Radiological Tumor Signs of Breast Cancer in UICC Stage I: Subanalysis of the Randomized Controlled Trial TOSYMA.

The randomized controlled, multicenter TOSYMA study showed a superiority of the combination of digital breast tomosynthesis and synthetic mammography (DBT+SM) over digital mammography (DM) in the detection rate of invasive breast cancer at stage UICC I. In this subanalysis, we compared the mammographic tumor signs of UICC I stage breast cancers detected in each study arm and stratified according to histological grade.This subanalysis included 49,462 women in the DBT+SM arm and 49,669 women in the DM arm after 1:1 randomization from July 2018 to December 2020. The mammographic abnormalities documented at the consensus conference were collected for breast cancers in stage UICC I based on various tumor signs (such as masses, microcalcifications, architectural distortions, or their combinations). The detection rates (per 10,000 screened women) were calculated with differentiation of grade 1 and grade 2 or 3 cancers.Grade 1 cancers were detected using DBT+SM in 6.5/10,000 screened women only by masses (+1.5/10,000 versus DM), in 2.4/10,000 (+1.6/10,000) by architectural distortions, and in 1.2/10,000 (+0.8/10,000) by microcalcifications. Combinations of tumor signs were present in 7.9/10,000 (+6.1/10,000) screened women. Grade 2 or 3 cancers were detected by DBT+SM in 13.7/10,000 by masses (+2.6/10,000 versus DM), in 4.9/10,000 by microcalcifications (+2.3/10,000), and in 3.6/10,000 by architectural distortions (+2.0/10,000). Combinations were present in 10.1/10,000 (+6.3/10,000) screened women.In DBT+SM screening, the detection rate of UICC I breast cancers is higher compared to DM: both, individual tumor signs and their combinations contribute to this finding. The detection rate of UICC I grade 2 or 3 cancers is higher in DBT+SM screening than in DM screening mainly due to the combination of tumor signs. · DBT+SM detects more grade 2 or 3-UICC I breast cancers than DM.. · This increase in detection rate results mainly from a combination of tumor signs.. · Nearly half of the increase relates to individual signs: masses, microcalcifications, and architectural distortions.. · Weigel S, Hense HW, Weyer-Elberich V et al. Radiological Tumor Signs of Breast Cancer in UICC Stage I: Subanalysis of the Randomized Controlled Trial TOSYMA. Rofo 2025; DOI 10.1055/a-2544-9085.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.20
自引率
5.60%
发文量
340
期刊介绍: Die RöFo veröffentlicht Originalarbeiten, Übersichtsartikel und Fallberichte aus dem Bereich der Radiologie und den weiteren bildgebenden Verfahren in der Medizin. Es dürfen nur Arbeiten eingereicht werden, die noch nicht veröffentlicht sind und die auch nicht gleichzeitig einer anderen Zeitschrift zur Veröffentlichung angeboten wurden. Alle eingereichten Beiträge unterliegen einer sorgfältigen fachlichen Begutachtung. Gegründet 1896 – nur knapp 1 Jahr nach der Entdeckung der Röntgenstrahlen durch C.W. Röntgen – blickt die RöFo auf über 100 Jahre Erfahrung als wichtigstes Publikationsmedium in der deutschsprachigen Radiologie zurück. Sie ist damit die älteste radiologische Fachzeitschrift und schafft es erfolgreich, lange Kontinuität mit dem Anspruch an wissenschaftliches Publizieren auf internationalem Niveau zu verbinden. Durch ihren zentralen Platz im Verlagsprogramm stellte die RöFo die Basis für das heute umfassende und erfolgreiche Radiologie-Medienangebot im Georg Thieme Verlag. Besonders eng verbunden ist die RöFo mit der Geschichte der Röntgengesellschaften in Deutschland und Österreich. Sie ist offizielles Organ von DRG und ÖRG und die Mitglieder der Fachgesellschaften erhalten die Zeitschrift im Rahmen ihrer Mitgliedschaft. Mit ihrem wissenschaftlichen Kernteil und dem eigenen Mitteilungsteil der Fachgesellschaften bietet die RöFo Monat für Monat ein Forum für den Austausch von Inhalten und Botschaften der radiologischen Community im deutschsprachigen Raum.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信